Biodexa Pharmaceuticals entered into a warrant inducement agreement on September 14, 2026, with an accredited holder to exercise all outstanding Series M, N, and O warrants at a reduced price of $1.05 per share. The transaction involves the exercise of 2,204,218 existing warrants, generating approximately $2.3 million in gross proceeds for the company before fees. In exchange, the holder receives two replacement Series P warrants for each exercised warrant, totaling up to 4,408,436 new ADSs with a five-year term and no price protection. The closing is expected on September 15, 2026, subject to customary conditions. Biodexa operates in the biopharmaceutical industry, developing innovative treatments for diseases such as cancer and diabetes.

Biodexa Pharmaceuticals PLC reported unaudited interim results for the six months ended June 30, 2026. R&D costs rose 75% to £2.92 million due to increased activity in the Serenta Phase 3 trial and manufacturing of the newly in-licensed MTX240 program. Administrative expenses decreased by 27% to £1.74 million, primarily driven by foreign exchange movements. The company incurred a net loss of £1.84 million, with finance income including a £2.38 million gain on equity-settled derivative liabilities. Cash balances fell to £3.23 million at June 30, 2026. Post-period, the company raised $3.5 million in gross proceeds through a direct offering and PIPE transaction completed on July 1, 2026. The filing highlights material uncertainties regarding going concern status due to anticipated funding needs in Q4 2026. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing innovative products for gastrointestinal cancers.

Biodexa Pharmaceuticals PLC shareholders approved a one-for-10,000 reverse stock split effective July 30, 2026, reducing the number of ordinary shares outstanding to 51,453,281. Concurrently, the ADS ratio adjusted from 500,000:1 to 50:1, maintaining proportional ownership and leaving the ADS count at 1,029,063. The company also received authority to allot up to £25,000,000 in new shares through 2029 and adopted new articles of association. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing innovative treatments for gastrointestinal cancers and other diseases.